Today, TD Asset Management Inc. Boosts Position in Alexion Pharmaceuticals Inc. (ALXN)

Today, TD Asset Management Inc. Boosts Position in Alexion Pharmaceuticals Inc. (ALXN)
TD Asset Management Inc. increased its stake in shares of Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) by 3.3% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 401,503 shares of the biopharmaceutical company’s stock after buying an additional 13,011 shares during the period. TD Asset Management Inc. owned about 0.18% of Alexion Pharmaceuticals worth $49,200,000 at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in the stock. Lockheed Martin Investment Management Co. boosted its stake in Alexion Pharmaceuticals by 48.0% in the third quarter. Lockheed Martin Investment Management Co. now owns 29,600 shares of the biopharmaceutical company’s stock valued at $3,627,000 after buying an additional 9,600 shares during the period. Honeywell International Inc. acquired a new stake in shares of Alexion Pharmaceuticals during the third quarter valued at $21,567,000. CG Asset Management LLC boosted its stake in shares of Alexion Pharmaceuticals by 8.7% in the third quarter. CG Asset Management LLC now owns 3,750 shares of the biopharmaceutical company’s stock valued at $460,000 after buying an additional 300 shares during the last quarter. State Treasurer State of Michigan boosted its stake in shares of Alexion Pharmaceuticals by 0.6% in the third quarter. State Treasurer State of Michigan now owns 78,274 shares of the biopharmaceutical company’s stock valued at $9,592,000 after buying an additional 500 shares during the last quarter. Finally, Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp acquired a new stake in shares of Alexion Pharmaceuticals during the third quarter valued at $5,625,000. 96.55% of the stock is owned by institutional investors.

Shares of Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) traded down 0.08% during mid-day trading on Friday, reaching $118.83. 472,545 shares of the company were exchanged. The stock has a 50 day moving average price of $122.91 and a 200-day moving average price of $129.23. The stock has a market capitalization of $26.64 billion, a P/E ratio of 72.46 and a beta of 1.45. Alexion Pharmaceuticals Inc. has a 12 month low of $110.56 and a 12 month high of $193.45.

Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings data on Thursday, October 27th. The biopharmaceutical company reported $1.23 earnings per share for the quarter, topping the consensus estimate of $1.04 by $0.19. The business earned $799 million during the quarter, compared to the consensus estimate of $787.07 million. Alexion Pharmaceuticals had a net margin of 12.46% and a return on equity of 10.58%. The company’s revenue was up 19.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.16 EPS. Analysts predict that Alexion Pharmaceuticals Inc. will post $4.64 earnings per share for the current year.

Several equities research analysts have recently weighed in on ALXN shares. Vetr cut shares of Alexion Pharmaceuticals from a “strong-buy” rating to a “strong sell” rating and set a $107.00 price target for the company. in a research report on Thursday, September 22nd. Piper Jaffray Cos. reaffirmed an “overweight” rating and issued a $185.00 price target on shares of Alexion Pharmaceuticals in a research report on Tuesday, August 16th. Brean Capital started coverage on shares of Alexion Pharmaceuticals in a research report on Tuesday, October 4th. They issued a “buy” rating and a $221.00 price target for the company. FBR & Co raised shares of Alexion Pharmaceuticals from an “underperform” rating to a “market perform” rating and set a $130.00 price target for the company in a research report on Friday, October 28th. Finally, Leerink Swann reaffirmed a “buy” rating and issued a $211.00 price target on shares of Alexion Pharmaceuticals in a research report on Monday, November 7th. One research analyst has rated the stock with a sell rating, six have given a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the stock. Alexion Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $173.36.

In other news, EVP Julie O’neill sold 650 shares of the business’s stock in a transaction that occurred on Friday, September 2nd. The shares were sold at an average price of $126.29, for a total transaction of $82,088.50. Following the completion of the sale, the executive vice president now owns 35,384 shares in the company, valued at approximately $4,468,645.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Edward Miller sold 367 shares of the business’s stock in a transaction that occurred on Friday, September 9th. The stock was sold at an average price of $128.32, for a total transaction of $47,093.44. Following the sale, the senior vice president now owns 16,519 shares of the company’s stock, valued at approximately $2,119,718.08. The disclosure for this sale can be found here. Insiders own 4.41% of the company’s stock.

Alexion Pharmaceuticals Company Profile

Related posts

Leave a Comment